After raising half a billion dollars, a secretive biotech gives an early look at its gene editing pipeline

Ryan Cross

Senior Science Correspondent

A secretive biotech startup developing a new form of gene editing is starting to give curious scientists a peek at its pipeline — without fully divulging …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After raising half a billion dollars, a secretive biotech gives an early look at its gene editing pipeline

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Versant unveils Light Horse with $62M and a partnership with Novartis

After lackluster 2024, biopharma industry prays stalled M&A will finally move into gear

Aiolos team reunites with $411M for new biotech with obesity drugs from China

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Cell therapy startup A2 Biotherapeutics nets $80M Series C

Leyden Labs gets $70M to test if nasal sprays can help protect against viruses

Af­ter rais­ing half a bil­lion dol­lars, a se­cre­tive biotech gives an ear­ly look at its gene edit­ing pipeline

Senior Science Correspondent

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

After raising half a billion dollars, a secretive biotech gives an early look at its gene editing pipeline